inclocibart (BAY 3018250) / Bayer - LARVOL DELTA

Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits. (PubMed, J Thromb Haemost) - "These findings indicate that BAY3018250 is a promising candidate for promoting endogenous or plasminogen activator-induced fibrinolysis."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis

SIRIUS: A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (clinicaltrials.gov) - P2 | N=258 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism

A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=39 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Cardiovascular

A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Bayer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular

A Study to Learn How Safe BAY3018250 Is, How It Moves Into, Through and Out of the Body, and How It Affects the Body in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Cardiovascular

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Cardiovascular

SIRIUS: A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (clinicaltrials.gov) - P2 | N=255 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism

SIRIUS: A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (clinicaltrials.gov) - P2 | N=255 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism